this page last modified
Anaplastic Large Cell Lymphoma, ALCL (Pediatric)
Reference for health information on this page: NIH/NCI
ALCL is usually classified as a type of NHL (non-Hodgkin's lymphoma) because the cancer cells express the marker CD30, although it does not resemble the other types of NHL. It usually is T-cell and can present in many different tissues: skin, bone, lymph nodes, brain, soft tissues, lungs, or liver. It is usually aggressive, but it can also go through periods of slow growth and occasionally resolves without treatment.
The World Health Organization (WHO) classifies anaplastic large cell lymphoma as a subtype of peripheral T-cell lymphoma.
See the cancer.gov web stie for current standard treatment plan(s) for childhood ALCL:
- NIH/NCI information (cancer.gov)
ACOR hosts a list for parents of children with ALCL:
Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children's oncology group. Sarah Alexander et al., Pediatric Blood & Cancer Volume 61, Issue 12, pages 2236–2242, December 2014. Abstract.
Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children's oncology group. Alexander S et al., Pediatr Blood Cancer, 2014 Aug 23. Abstract.
Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Richard Delarue et al., The Lancet Oncology, Volume 14, Issue 6, Pages 525 - 533, May 2013. Abstract.
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. Barbara Pro et al., JCO, epub May 21, 2012. Abstract.
Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood. Marta Pillon et al., Pediatric Blood & Cancer, epub 2 MAR 2012. Abstract.
Prognostic Impact of Morphologic and Phenotypic Features of Childhood ALK-Positive Anaplastic Large-Cell Lymphoma: Results of the ALCL99 Study. Laurence Lamant et al., Journal of Clinical Oncology, epub November 14, 2011. Abstract.
Pediatric Blood & CancerFDA news release, August 19, 2011. FDA approves Adcetris to treat two types of lymphoma. "The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL)." "Adcetris is an antibody-drug conjugate [ADC] that combines an antibody and drug, allowing the antibody to direct the drug to a target on lymphoma cells known as CD30." Also known as SGN-35.
FDA approves Adcetris to treat two types of lymphoma. Press release. "The U.S. Food and Drug Administration today approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL). . . . Adcetris may also be used in patients with ALCL whose disease has progressed after one prior chemotherapy treatment." Aug. 19, 2011.
Long-term survival of a child with refractory anaplastic large cell lymphoma following therapy with an antisense oligonucleotide, topotecan, and vinblastine. Grazyna Wrobel et al., Hematological Oncology, epub 2 AUG 2011. Abstract.
Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: Report of the ALCL99 randomised trial. Grazyna Wrobel et al., Pediatric Blood & Cancer Pediatric Blood & Cancer Early View, first published online: 28 JAN 2011. Abstract.
Advanced-stage anaplastic large-cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: A report from the Children's Oncology Group. ASCO site abstract. J. M. Kraveka et al., J Clin Oncol 28:15s, 2010 (suppl; abstr 9511).
Vinblastine in Children and Adolescents With High-Risk Anaplastic Large-Cell Lymphoma: Results of the Randomized ALCL99-Vinblastine Trial. Marie-Cécile Le Deley et al., American Society of Clinical Oncology, Published online before print August 2, 2010. Abstract. "Adding vinblastine during induction and as maintenance for a total treatment duration of 1 year significantly delayed the occurrence of relapses but did not reduce the risk of failure."
Anaplastic large cell lymphoma: a critical evaluation of cytomorphological features in seven cases. Das P, Iyer VK, Mathur SR, Ray R. Cytopathology. 2010 Aug;21(4):251-8. Abstract.
Gene Expression Profiling Uncovers Molecular Classifiers for the Recognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms. Roberto Piva et al., JCO Early Release, published online ahead of print Feb 16 2010. Abstract.
The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. E Drakos et al., Leukemia (2009) 23, 22902299. Abstract.
Promise of a new drug: Boston Globe Article, 2009. The drug is "brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeting CD30. SGN-35 is in late-stage trials for the treatment of relapsed and refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL)."
Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy. Brunangelo Falini, Maria Paola Martelli. Haematologica, Vol 94, Issue 7, 897-900, 2009. Abstract.
Long-term disease control of refractory anaplastic large cell lymphoma with vinblastine. Garner R, Li Y, Gray B, Zori R, Braylan R, Wall J, Hunger SP. J Pediatr Hematol Oncol. 2009 Feb;31(2):145-7. Abstract.
Diagnosis of paediatric anaplastic large-cell lymphoma: a historical perspective from a single institution. Lucas Moreno et al., Clinical and Translational Oncology, Volume 11, Number 5 / May, 2009, pp. 318-321. Abstract.
Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Marie-Cécile Le Deley et al., Blood, 1 February 2008, Vol. 111, No. 3, pp. 1560-1566. Abstract.
Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941. Eric J. Lowe et al., Pediatric Blood & Cancer, Volume 52 Issue 3, pp. 335-339, 2008. Abstract.
Flow Cytometric Immunophenotyping of Anaplastic Large Cell Lymphoma. Tariq Muzzafar et al., Archives of Pathology and Laboratory Medicine: Vol. 133, No. 1, pp. 4956. Full text.
Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941. Eric J. Lowe et al., Pediatric Blood & Cancer, Volume 52 Issue 3, Pages 335 - 339, 2008. Abstract.
Single-Drug Vinblastine As Salvage Treatment for Refractory or Relapsed Anaplastic Large-Cell Lymphoma: A Report From the French Society of Pediatric Oncology. Laurence Brugières et al, JCO Early Release, published online ahead of print Sep 8 2009. Abstract.
Long-term remission of children with relapsed and secondary anaplastic large cell non-Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide. Stockklausner C, Behnisch W, Mechtersheimer G, Mšller P, Kulozik AE. Pediatr Blood Cancer. 2008 Jan;50(1):126-9. Abstract.
Anaplastic Large Cell Lymphomas: A Study of 75 Pediatric Patients -- Pediatric and Developmental Pathology. Pediatric and Developmental Pathology, Volume 10, Issue 3 (May-June 2007), pp. 181191. D'Amore, E.S.G., et al. Describes the morphologic and immunophenotypic features of 75 cases of pediatric anaplastic large cell lymphoma (ALCL). According to the World Health Organization classification, 49 cases were common subtype ALCL, and respectively, 3, 6, and 17 cases were small cell, lymphohistiocytic, or mixed histologic variants. Anaplastic lymphoma kinase positivity was detected in 90.7% of the tumors and, using a panel of 9 T-cell surface markers, 88% could be assigned to the T-cell lineage. Abstract.
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Ansell, S.M., et al. Journal of Clinical Oncology. Abstract. Journal of Clinical Oncology, Vol 25, No 19 (July 1), 2007: pp. 2764-2769.
Antineoplastic agents for pediatric anaplastic large cell lymphoma: Vinblastine is the most effective in vitro. Muto A, Nakagawa A, Shimomura Y, Kitagawa Y, Tsurusawa M. Leuk Lymphoma. 2005 Oct;46(10):1489-96. Abstract.
Anaplastic large cell lymphoma treated with a leukemia-like therapy: report of the Italian Association of Pediatric Hematology and Oncology (AIEOP) LNH-92 protocol. Rosolen A, Pillon M, Garaventa A, Burnelli R, d'Amore ES, Giuliano M, Comis M, Cesaro S, Tettoni K, Moleti ML, Tamaro P, Visintin G, Zanesco L. Cancer. 2005 Nov 15;104(10):2133-40. Abstract.
Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. Brugi¸res L, Quartier P, Le Deley MC, Pacquement H, Perel Y, Bergeron C, Schmitt C, Landmann J, Patte C, Terrier-Lacombe MJ, Delsol G, Hartmann O. Ann Oncol. 2000 Jan;11(1):53-8. Abstract.
These pages are intended for informational purposes only and are not intended to render medical advice. The information provided on Ped Onc Resource Center should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you suspect your child has a health problem, you should consult your health care provider.